BioMarin Pharmaceutical (BMRN) Stock Price, Quote, News & History | Benzinga

BioMarin Pharmaceutical Inc (BMRN) Stock Price, Quote, News & History

BMRNNASDAQ

Trade with Public

Trade with Public

$66.70

-0.98-1.45%

At close: Aug 21, 5:00 PM EST

$66.41

-0.29-0.43%

After Hours: Aug 21, 6:24 PM EST

M&A: Alesta Therapeutics announced it will be acquired by BioMarin Pharmaceutical (BMRN) on Tuesday, August 18, 2026 for $275M

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$67.55

Close

$66.70

Volume / Avg.

1.59M / 2.15M

Day Range

$66.52 - $68.34

52 Wk Range

49.26 - 70.98

Market Cap

$12.84B

P/E Ratio

182.89

Dividend Yield

-

Exchange

NASDAQ

RSI

58

Short Interest

6.49%

Days to Cover

7.42

Recent BioMarin Pharmaceutical Inc. News

This Baidu Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday

Wall Street analysts change outlook on top stocks, including BIDU and BMO. See their ratings and price targets on Benzinga's analyst page.

Avi Kapoor

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Check out opinions and coverage on Benzinga.

Avi Kapoor

BioMarin Seeks to Strengthen Market Position in Rare Bone Disease Treatment

BioMarin Pharmaceutical agrees to acquire Alesta Therapeutics for $275 million upfront, securing ALE1 for rare bone disease treatment.

Vandana Singh

BioMarin Reveals Dwarfism Study Data, Stock Soars

BioMarin stock climbed after Phase 3 VOXZOGO data showed significant growth improvements in children with hypochondroplasia.

Vandana Singh

Top 3 Health Care Stocks That Are Set To Fly In March

Opportunity to buy undervalued health care stocks. RSI is a momentum indicator that compares strength on up and down days. Here's a list of oversold stocks with RSI near or below 30.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

857.09M

Investing Cash Flow (TTM)

-4.75B

Financing Cash Flow (TTM)

3.55B

Free Cash Flow (TTM)

725.08M

Capital Expenditure (TTM)

-132.01M

Net Change in Cash (TTM)

-340.14M

Analyst Trends and Forecast

4

1

Feb

3

1

Mar

7

3

May

1

Jul

6

2

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.7

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$16.24B

PE Ratio (TTM)

182.89

PE Ratio (FWD)

13.64

PEG Ratio (TTM)

0.53

PS Ratio (TTM)

3.90

PB Ratio (TTM)

2.07

Earnings Yield % (TTM)

0.55%

Earnings Yield % (FWD)

7.33%

EV / EBITDA (TTM)

42.59

Price / EBITDA (TTM)

34.41

Price / Free Cash Flow (TTM)

18.31

Book Value / Share

$32.66

Company Debt

Total Debt

$4.19B

LT Debt

$3.53B

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$874.01M

Debt to Equity

0.66

Issuance of Debt (TTM)

$3.65B

Repayment of Debt (TTM)

-

Key Statistics

Open

$67.55

Close

$66.70

Volume / Avg.

1.59M / 2.15M

Day Range

$66.52 - $68.34

52 Wk Range

49.26 - 70.98

Market Cap

$12.84B

P/E Ratio

182.89

Dividend Yield

-

Exchange

NASDAQ

RSI

58

Short Interest

6.49%

Days to Cover

7.42

About

Sector

Health Care

Industry

Biotechnology

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex ...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy BioMarin Pharmaceutical (BMRN) stock?

A

You can purchase shares of BioMarin Pharmaceutical (NASDAQ:BMRN) through any online brokerage.

View our list of the best stock brokerages

Q

Who are BioMarin Pharmaceutical (BMRN) competitors?

A

Other companies in BioMarin Pharmaceutical’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for BioMarin Pharmaceutical (BMRN) stock?

A

BioMarin Pharmaceutical has a consensus price target of $90.26.

Q

What is the current price for BioMarin Pharmaceutical (BMRN)?

A

The stock price for BioMarin Pharmaceutical (NASDAQ: BMRN) is $66.41 last updated August 21, 2026 at 6:24 PM EDT.

Q

Does BioMarin Pharmaceutical (BMRN) pay a dividend?

A

There are no upcoming dividends for BioMarin Pharmaceutical.

Q

When is BioMarin Pharmaceutical (NASDAQ:BMRN) reporting earnings?

A

BioMarin Pharmaceutical does not have any upcoming earnings scheduled.

Q

Is BioMarin Pharmaceutical (BMRN) going to split?

A

There is no upcoming split for BioMarin Pharmaceutical.

Q

What sector and industry does BioMarin Pharmaceutical (BMRN) operate in?

A

BioMarin Pharmaceutical is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.